Literature DB >> 23418762

Hereditary hemochromatosis.

Brian K Crownover1, Carlton J Covey.   

Abstract

Hereditary hemochromatosis is an autosomal recessive disorder that disrupts the body's regulation of iron. It is the most common genetic disease in whites. Men have a 24-fold increased rate of iron-overload disease compared with women. Persons who are homozygous for the HFE gene mutation C282Y comprise 85 to 90 percent of phenotypically affected persons. End-organ damage or clinical manifestations of hereditary hemochromatosis occur in approximately 10 percent of persons homozygous for C282Y. Symptoms of hereditary hemochromatosis are nonspecific and typically absent in the early stages. If present, symptoms may include weakness, lethargy, arthralgias, and impotence. Later manifestations include arthralgias, osteoporosis, cirrhosis, hepatocellular cancer, cardiomyopathy, dysrhythmia, diabetes mellitus, and hypogonadism. Diagnosis requires confirmation of increased serum ferritin levels and transferrin saturation, with or without symptoms. Subtyping is based on genotypic expression. Serum ferritin measurement is the most useful prognostic indicator of disease severity. Liver biopsy is performed to stage the degree of fibrosis with severe ferritin elevation or transaminitis, or to diagnose nonclassical hereditary hemochromatosis in patients with other genetic defects. Treatment of hereditary hemochromatosis requires phlebotomy, and the frequency is guided by serial measurements of serum ferritin levels and transferrin saturation. Iron avidity can result from overtreatment. If iron avidity is not suspected, it may mimic undertreatment with persistently elevated transferrin saturation. Dietary modification is generally unnecessary. Universal screening for hereditary hemochromatosis is not recommended, but testing should be performed in first-degree relatives of patients with classical HFE-related hemochromatosis, those with evidence of active liver disease, and patients with abnormal iron study results. Screening for hepatocellular carcinoma is reserved for those with hereditary hemochromatosis and cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418762

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  40 in total

Review 1.  Use of magnetic resonance imaging to monitor iron overload.

Authors:  John C Wood
Journal:  Hematol Oncol Clin North Am       Date:  2014-08       Impact factor: 3.722

2.  Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents.

Authors:  Suraj D Serai; Robert J Fleck; Charles T Quinn; Bin Zhang; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2015-05-26

Review 3.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

4.  Improvements in cardiac function detected using echocardiography in patients with hereditary haemochromatosis.

Authors:  Danielle Byrne; John Patrick Walsh; Caroline Daly; Susan McKiernan; Suzanne Norris; Ross T Murphy; Gerard King
Journal:  Ir J Med Sci       Date:  2019-05-20       Impact factor: 1.568

Review 5.  Recent advances in hemochromatosis: a 2015 update : a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia.

Authors:  Dilum Ekanayake; Clinton Roddick; Lawrie W Powell
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

Review 6.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

7.  Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload.

Authors:  Aaron M Wortham; Devorah C Goldman; Juxing Chen; William H Fleming; An-Sheng Zhang; Caroline A Enns
Journal:  J Biol Chem       Date:  2020-02-13       Impact factor: 5.157

8.  Cytokine and Gene Expression Profiling in Patients with HFE-Associated Hereditary Hemochromatosis according to Genetic Profile.

Authors:  Heidi Kristine Grønlien; Trine Eker Christoffersen; Camilla Furlund Nystrand; Lamya Garabet; Terje Syvertsen; Morten K Moe; Ole Kristoffer Olstad; Christine Monceyron Jonassen
Journal:  Acta Haematol       Date:  2020-12-16       Impact factor: 2.195

9.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

10.  Effect of the Hemochromatosis Mutations on Iron Overload among the Indian β Thalassemia Carriers.

Authors:  Anita H Nadkarni; Aradhana A Singh; Stacy Colaco; Priya Hariharan; Roshan B Colah; Kanjaksha Ghosh
Journal:  J Clin Lab Anal       Date:  2016-08-26       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.